New preclinical data on MIV-818 accepted for presentation at EASL’s HCC Summit in March
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new preclinical data for MIV-818 will be presented at the HCC Summit 2018, organized by the European Association for the Study of the Liver (EASL), on 1-3 March 2018. MIV-818 is Medivir’s proprietary nucleotide prodrug that is being developed for the treatment of hepatocellular carcinoma and other liver cancers. Two presentations will be made at the conference, covering the preclinical efficacy and pharmacokinetic profile of MIV-818. The abstracts accepted for presentation at the HCC Summit 2018 are as follows: